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Heart failure (HF) is a shared manifestation of several cardiovascu-
lar pathologies, including hypertension and myocardial infarction,
and a limited repertoire of treatment modalities entails the asso-
ciated morbidity and mortality remain high. Impaired nitric oxide
(NO)-guanylyl cyclase (GC)-cyclic guanosine-3’,5’-monophosphate
(cGMP) signaling, underpinned in part by up-regulation of cyclic
nucleotide-hydrolyzing phosphodiesterase (PDE) isozymes, con-
tributes to the pathogenesis of HF, and interventions targeted
to enhancing cGMP have proven effective in pre-clinical models
and patients. Numerous PDE isozymes coordinate the regulation
of cardiac cGMP in the context of HF; PDE2 expression and activity
is up-regulated in experimental and human HF, but a well-defined
role for this isoform in pathogenesis has yet to be established,
certainly in terms of cGMP signaling. Herein, using a selective
pharmacological inhibitor of PDE2, BAY 60-7550, and transgenic
mice lacking either NO-sensitive guanylyl cyclase α1 (GC-1α-/-)
or natriuretic peptide-responsive guanylyl cyclase-A (GC-A-/-), we
demonstrate the blockade of PDE2 promotes cGMP signaling to
offset the pathogenesis of experimental HF (induced by pressure-
overload or sympathetic hyper-activation), reversing the develop-
ment of left ventricular hypertrophy, compromised contractility
and cardiac fibrosis. Moreover, we show that this beneficial phar-
macodynamic profile is maintained in GC-A-/- mice, but absent in
animals null for GC-1α or treated with a NO synthase inhibitor, re-
vealing that PDE2 inhibition preferentially enhances NO/GC/cGMP
signaling in the setting of HF to exert a wide-ranging protection
to preserve cardiac structure and function. These data substantiate
the targeting of PDE2 in HF as a tangible approach to maximize
myocardial cGMP-signaling and enhancing therapy.
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INTRODUCTION
Left ventricular hypertrophy (LVH) and subsequent heart failure
(HF) are common to many cardiovascular disorders, including
hypertension and myocardial infarction, and after age represent
the most significant independent risk factors for cardiovascular
morbidity and mortality(1). Current therapy focuses on reducing
excess fluid load (e.g. diuretics) and blocking neuro-hormonal
pathways (e.g. β-blockers, angiotensin converting enzyme [ACE]
inhibitors)(2). Unfortunately, these interventions do not offer a
cure but only slow deterioration in LV function. Consequently,
HF is still associated with a 5 year survival rate of ∼50%; the
disorder therefore represents a clear unmet medical need.
Generation of the second messenger cyclic GMP (cGMP) by
activation of NO- (α1β1 [GC-1] and α2β1 [GC-2])(3) and natri-
uretic peptide- (GC-A and GC-B)(4) sensitive guanylyl cyclases
plays a key role in maintaining physiological cardiac contractility
and integrity, and in offsetting the pathogenesis of LVH and
HF(5). From a homeostatic perspective, endothelial (eNOS) and
neuronal (nNOS) NO synthase appear to function in a comple-
mentary manner; eNOS-derived NO is thought to contribute to
LV compliance, β-adrenergic inotropy, and amplifies parasympa-
thetic innervation, whereas nNOS-generated NO regulates basal
myocardial inotropy and lusitropy via inhibition of ICa, sympatho-
vagal balance, and limits the activity of oxidases(6, 7). Indeed,
in LVH such protective NO-mediated systems are depressed, in
part due to diminished NO bioavailability and elevated GC-1/2
heme oxidation(8-10), driven by an increase in the production
of reactive oxygen species, particularly by NADPH oxidase iso-
forms(11). Likewise, natriuretic peptides maintain cardiac struc-
ture and function in both physiological and pathological settings,
as illustrated by the hypertrophic, fibrotic cardiac phenotype in
transgenic animals lacking these mediators or cognate receptors,
and the exacerbated response of such mice to cardiac stress (12-
14).
From a pharmacological standpoint, NO donors, GC-1/2
(‘sGC’) stimulators and exogenously applied natriuretic peptides
have been shown to decrease hypertrophy in cardiomyocytes
and offset the development of HF in animal models and pa-
tients(15, 16). The common generation of cGMP and G-kinase
activation affects a plethora of maladaptive, hypertrophic path-
ways including functional inhibition of Ca2+ channels and Ca2+
sequestration(17, 18), calcineurin/NFAT (nuclear factor of acti-
vated T-cells) signaling(19), blockade of regulators of G-protein
signaling [RGS] proteins(20), transient receptor potential cation
channel (TRPC)(21) and myosin binding protein (MBP)-C(22).
This cardioprotective profile of cGMP in HF is exemplified
Significance
The morbidity and mortality associated with heart failure (HF)
are unacceptably high. Cyclic guanosine-3’,5’-monophosphate
(cGMP) plays a key role in preserving cardiac structure and
function, and therapeutically targeting cGMP in HF has shown
promise in experimental models and patients. Phosphodi-
esterases (PDEs) metabolize and curtail the actions of cGMP
(and cyclic adenosine-3’,5’-monophosphate, cAMP) and in-
creased PDE activity is thought to contribute to HF pathogen-
esis. Herein, we show that inhibition of one specific isoform,
PDE2, enhances the salutary effects of cGMP in the context of
HF, and that this beneficial action facilitates a distinct path-
way, driven by nitric oxide, that is impaired in this disorder.
These observations validate PDE2 inhibitors as a demonstrable
means of boosting cardiac cGMP and advancing HF therapy.











































































































































Fig. 1. PDE2 inhibition reverses experimental HF in response to pressure-
overload. (A) Echocardiographic indices of heart structure & function, (B)
cardiac fibrosis, and (C) cardiomyocyte size in sham mice and animals under-
going abdominal aortic constriction (AAC) for 3 weeks (3w) or 6 weeks (6w)
in the absence and presence of BAY 60-7550 (10 mg/kg/day; p.o.; initiated at
3w). Data are expressed as mean±sem and analyzed by one-way ANOVA with
Bonferroni post hoc test. *p<0.05 versus sham, #p<0.05 v AAC (6w). n=12-18.
by positive clinical outcomes with the dual neutral endopepti-
dase (an enzyme that inactivates natriuretic peptides) inhibitor-
angiotensin receptor blocker LCZ696(23) and the sGC stimulator
vericiguat(15).
An alternative therapeutic strategy to augment cGMP sig-
naling for cardioprotection is inhibition of phosphodiesterases
(PDEs). Cardiac cGMP concentrations are dynamically regulated
byGC-driven synthesis in cooperationwith degradationmediated
by PDEs, a family of enzymes that hydrolyze cGMP and its sibling
cyclic adenosine-3’-5’-monophosphate (cAMP)(24). In the heart,
PDE isozymes 1, 2, 5 and 9 are believed to exert the most influ-
ential effects on cGMP signaling(25-28). Of these, PDE1 is the
major isoform expressed in the healthy myocardium(29), whereas
PDE5 is only minimally expressed under physiological conditions
but significantly up-regulated in the failing myocardium(30, 31).
In HF, inhibition of cGMP-metabolizing PDEs 1, 5 & 9 slows
pathogenesis(27, 28); indeed, upregulation of expression and/or
activity of PDEs is thought to underpin the diminution of cGMP
signaling characteristic of HF(32). Several small clinical studies
support a beneficial role for PDE5i inHF(33-36), but theRELAX
trial, a randomized, double-blinded evaluation of sildenafil in HF
patients with preserved ejection fraction (HFpEF) showed no
significant benefit(37). This disappointing outcome intimates that
if the therapeutic activity of cGMP is to be harnessed optimally,
Fig. 2. The beneficial effect of PDE2 inhibition in pressure overload-
induced HF is not underpinned by acute changes in cardiac function. (A)
Coronary perfusion pressure (CPP), left ventricular developed pressure (LVDP)
and heart rate (HR) in WT sham mice or animals subjected to 6 weeks of
abdominal aortic constriction (ACC) in the absence and presence of BAY 60-
7550 (10 mg/kg/day; p.o.; initiated at 3w). CPP, LVDP and HR in sham mice
and animals subjected to 6w AAC in the absence and presence of BAY 60-
7550 (10 mg/kg/day; p.o.; initiated at 3w) following the addition of increasing
doses of (B) ANP, (C) SNP, and (D) isoproterenol (ISO). Data are expressed as
mean±sem and analyzed by one-way ANOVA with Bonferroni post hoc test
(A) or two-way ANOVA (B-D). *p<0.01 v sham or #p<0.05 v AAC (6w; A) and
**p<0.01, ***p<0.001 versus AAC (6w; C-D). n=6-12.
interventions targeting alternate, or more likely multiple, cGMP
synthetic and/or degradative pathways will be necessary.
A relatively unexplored mechanism that might address this
therapeutic deficiency is PDE2. This ‘cGMP-stimulated’ PDE
metabolizes both cGMP and cAMP, and possesses a GAF-B
domain(38) within its N-terminus(24) that acts as a negative feed-
back loop to expedite cyclic nucleotide hydrolysis in the presence
of cGMP (akin to PDE5). Three PDE2 splice variants have been
identified and are expressed in a wide variety of cells and tissues
including the heart, platelets and endothelium(24); moreover,
PDE2 expression is increased in both animals and patients with
HF(39). PDE2 isozymes are kinetically indistinguishable, but the
2A2 and 2A3 variants have a N-terminal membrane localization
motif that results in a predominantly particulate distribution.
This cellular localization seems key to the functioning of PDE2
in the heart due to compartmentalization of cGMP signaling
in cardiomyocytes(26, 40) and has been speculated to play a
key role in modulating the development of LVH and HF. For
example, up-regulation of PDE2 expression and activity may be
protective by opposing the effects of sympathetic activation via











































































































































Fig. 3. PDE2 inhibition reverses pressure overload-induced HF in GC-A-/-
mice. (A) Echocardiographic indices of heart structure & function, (B) cardiac
fibrosis, and (C) cardiomyocyte size in sham mice and animals undergoing
abdominal aortic constriction (AAC) for 3 weeks (3w) or 6 weeks (6w) in the
absence and presence of BAY 60-7550 (10mg/kg/day; p.o.; initiated at 3w).
Data are expressed as mean±sem and analyzed by one-way ANOVA with
Bonferroni post hoc test. *p<0.05 v sham; #p<0.05 v AAC (6w). n=6-12.
has been reported to lower HR and maintain LV function and
subdue arrhythmogenesis in experimental MI(43). Alternatively,
PDE2 inhibition can prevent the hydrolysis of a localized pool of
cAMP leading to PKA-dependent phosphorylation of NFAT and
an anti-hypertrophic response(44). However, these studies have
focused primarily on modulation of cAMP levels (i.e. PDE2 as
a ‘cAMP-hydrolase’) of which chronic, widespread increases are
known to cause higher mortality in HF patients(45). In contrast,
there is a paucity of in vivo evidence evaluating the influence of
PDE2-mediated cGMP hydrolysis in LVH and HF, although in
the setting of pulmonary hypertension (PH) our recent work has
highlighted the beneficial effects of PDE2 inhibition in dimin-
ishing the vascular remodeling and right ventricular hypertrophy
(RVH)(46). Herein, we address this deficit by establishing a
cGMP-dependent cardioprotective effect of PDE2 in pre-clinical
models of LVH and HF, and identify the guanylyl cyclase source
of cGMP that drives this process.
METHODS
All experiments were conducted according to the Animals (Scientific Pro-
cedures) Act 1986, United Kingdom and had approval from a local ethics
committee. Animals were housed in a temperature-controlled environment
in a 12-hour light–dark cycle. Food and water were accessible ad libitum.
Genotyping
Genomic DNA was prepared from ear biopsies for analysis by polymerase
chain reaction (PCR) using standard cycling parameters using the forward
Fig. 4. Obligatory role of GC-1/NO signaling in the beneficial effects of
PDE2 inhibition in HF. (A) Echocardiographic indices of heart structure &
function, (B) cardiac fibrosis, and (C) cardiomyocyte size in sham mice and
animals undergoing abdominal aortic constriction (AAC) for 3 weeks (3w) or
6 weeks (6w) in the absence and presence of BAY 60-7550 (10 mg/kg/day;
p.o.; initiated at 3w). Data are expressed as mean±sem and analyzed by one-
way ANOVA with Bonferroni post hoc test. *p<0.05, **p<0.01, ***p<0.001 v
sham. n=6-12.
and reverse primers stated in SI Appendix, Table S1, as we have described
previously(47).
Generation of GC-1α knockout mice
This novel GC-1α-/- strain was developed at Pfizer Inc. Briefly, heterozy-
gous mouse embryonic stem cells containing one GC-1α-/- allele modified by
homologous recombination were obtained from Deltagen (San Carlos, CA).
Long distance PCR was used to generate a 5.7 kb 5’ homology arm and a 3.6
kb 3’ homology arm flanking a 5.3 kb deletion encompassing exons 6 and 7 of
the mouse GC-1α gene (GenBank accession number NM 021896). Exons 6 and
7 were replaced with a Lac-Z/Neor selection cassette, disrupting the 3’ end of
the cyclase domain (SI Appendix, Figure S1). Mouse 129P2/OlaHsd (E14) cells
were transformed by established techniques(48) and G418-resistant colonies
were selected. Expanded clones were screened via long distance PCR and
Southern analysis. One clone with the correctly modified GC-1α allele was
used to generate the mouse line via standard blastocyst injection(48).
Successful deletion of GC-1α was confirmed by immunoblot, assay of
enzyme activity in lung homogenates, functional vascular pharmacology in
response to NO-donor, and measurement of mean arterial blood pressure.
(SI Appendix, Figure S1). The body weight of WT and GC-1α-/- mice did not
differ significantly at the time of experimentation (WT: 30.92±0.63g, GC-1α-/-:
30.95±0.65g; P>0.05; n=10).
Expression: Lungs were homogenized ice-cold 50 mM Tris pH 7.5, 0.1
mM EDTA, 0.1 mM EGTA, 0.1% 2-mercaptoethanol containing protease
inhibitor cocktail (Roche) using an Ultra Turrax T8 disperser (IKA Works
Inc.). Homogenates were centrifuged at 1000 x g for 30 min at 4oC, the
supernatants were collected and protein concentration determined using
the Bio-Rad method according to the manufacturer’s instructions. 20 μg
of lung supernatant protein was separated by 7% SDS-PAGE using Novex
Tris-Acetate gel system (Invitrogen) and proteins were transferred to nitro-











































































































































Fig. 5. PDE2 inhibition reverses experimental HF in response to sympathetic
hyperactivation. (A) Echocardiographic indices of heart structure & function,
(B) cardiac fibrosis, and (C) cardiomyocyte size in sham mice and animals
administered isoproterenol (20mg/kg/day; s.c.) for 2 weeks in the absence
and presence of BAY 60-7550 (10 mg/kg/day; p.o.; initiated at 1w). Data are
expressed as mean±sem and analyzed by one-way ANOVA with Bonferroni
post hoc test. *p<0.05 versus sham, #p<0.05 v AAC (6w). n=6-12.
used to confirm uniformity of protein loading. Membranes were blocked
with 5% milk (Santa Cruz Biotechnology) dissolved in TBS-Tween 20, pH 7.4
(ScyTek Laboratories) for 1.5 h at room temperature. For the detection of
GC-1α, membranes were incubated with polyclonal rabbit anti-GC-1α serum
(Alexis Biochemicals, 1:2000 dilution) and for the GC-1β subunit detection
with polyclonal rabbit anti-GC-1β affinity isolated antibody (1:1000 dilution,
Alexis Biochemicals) for 1 h at room temperature. Membranes were washed
with TBS-Tween 20, pH 7.4 buffer and incubated with 2° antibody (goat
anti-rabbit HRP-conjugated IgG, 1:2500 dilution; Pierce) for 1 h at room
temperature and followed by four washes in TBS-Tween, pH 7.4. Dilutions
of primary and secondary antibodies were prepared in TBS-Tween 20 buffer.
Antibody reactivity was detected using SuperSignal West Dura Extended
Duration Substrate (ThermoFisher Scientific, Waltham, MA, USA) and Kodak
film (Sigma, St. Louis, MO, USA).
Activity: Assays were performed in 100 μL containing of 50 mM Tris,
pH 7.4; 1 mM DTT; 0.2 mM GTP; 5 mM MgCl2, 0.5 mM IBMX, and 1-10 μg
of lung extract protein. DETA-NONOate (100 μM) was included as specified.
Reactions were started by addition of substrate, incubated for 60 min at 37oC
and terminated with the addition of 20 mM EDTA. Cyclic GMP was then
quantified using the CatchPointTM cGMP Fluorescent Assay Kit (Molecular
Devices, Sunnyvale, CA, USA) according to the manufacturer’s instructions.
Vascular reactivity: The vascular reactivity of mouse thoracic aortic
vascular ring preparations was determined using classical tissue bath phar-
macology, as we have described previously(49).
Blood pressure & heart rate: Blood pressure was recorded in conscious
freely moving mice using radiotelemetric transmitters (TA11PA-C10, Data
Sciences International, Minneapolis, USA) implanted into the aortic arch, as
we have described previously(49).
Pressure overload-induced HF
Pressure-overload LVH and cardiac dysfunction were induced by per-
forming abdominal aortic constriction (AAC) at the suprarenal level. Male
Fig. 6. PDE2 inhibition reverses sympathetic hyperactivation-induced HF
in GC-A-/- mice. (A) Echocardiographic indices of heart structure & function,
(B) cardiac fibrosis, and (C) cardiomyocyte size in sham mice and animals
administered isoproterenol (20 mg/kg/day; s.c.) for 2 weeks in the absence
and presence of BAY 60-7550 (10 mg/kg/day; p.o.; initiated at 1w). (D)
Survival in sham mice and animals administered isoproterenol (20 mg/kg/day;
s.c.) for 2 weeks in the absence and presence of BAY 60-7550 (10mg/kg/day;
p.o.; initiated at day 0). Data are expressed as mean±sem and analyzed by
one-way ANOVA with Bonferroni post hoc test (A-C) or as a Kaplan-Meier
survival plot (D). *p<0.05 v sham; #p<0.05 v AAC (6w; A-C) or GC-A-/- + ISO
(D). n=6-12.
wild type (WT), GC-1α-/- (as described above) and GC-A-/- (kind gift of Prof. O.
Smithies, University of North Carolina) mice (21–23 g; offspring of heterozy-
gote parents to enable use of corresponding WT littermate controls) were
anesthetized (1.5% isoflurane in O2), body temperature maintained at 37
oC
and the analgesic buprenorphine (0.1 mg/kg) administered (i.m.). An incision
was made in the abdominal cavity, and the abdominal aorta was separated
from the surrounding tissue at the suprarenal level. Aortic constriction was
performed by tying a 4-0 surgical thread against a 25-gauge needle between
the superior mesenteric and renal arteries. This produces a 30% constriction
of the luminal diameter(50). For sham operations, the 4-0 surgical thread was
passed under the aorta and removed without tying it against the needle. In
some studies, WT mice undergoing AAC were administered the NOS inhibitor
L-NG-nitroarginine methylester (L-NAME; 100 mg/kg/day) via the drinking
water for 7 days prior to and during the AAC model.
Chronic sympathetic activation-induced HF
Sustained sympathetic activation is characteristic of HF and can be
recapitulated in pre-clinical models using chronic dosing with the β-agonist
isoproterenol(51). Male WT, GC-1-/- and GC-A-/- mice (24-25 g;) were infused
subcutaneously with isoproterenol (20 mg/kg/day, 14 days; Sigma-Aldrich,
Poole, UK) via osmotic mini-pumps (model 1002, Alzet, Cupertino, CA). Saline
containing 0.5% ascorbic acid was used as the solvent for isoproterenol to
avoid catecholamine oxidation over time.
Treatment regimens
Animals were assigned randomly to receive the selective PDE2 inhibitor
BAY 60-7550(52) (10 mg/kg/day; kind gift of Dr. J.-P. Stasch & P. Sandner,
Bayer AG, Wuppertal, Germany) or vehicle control (0.5% carboxycellulose











































































































































Fig. 7. Obligatory role of GC-1/NO signaling in the beneficial effects of
PDE2 inhibition in sympathetic hyperactivation-induced HF. (A) Echocardio-
graphic indices of heart structure & function, (B) cardiac fibrosis, and (C)
cardiomyocyte size in sham mice and animals administered isoproterenol (20
mg/kg/day; s.c.) for 2 weeks in the absence and presence of BAY 60-7550
(10 mg/kg/day; p.o.; initiated at 1w). Data are expressed as mean±sem and
analyzed by one-way ANOVA with Bonferroni post hoc test. *p<0.05 v sham.
n=6-12.
or 1 week after isoproterenol infusion (i.e. after the HF phenotype had
developed).
In vivo cardiac functional assessments
In vivo cardiac morphology and function were assessed by M-mode
echocardiography using a VisualSonics Vevo 770 echocardiographic system
and a 30 MHz transducer. Mice were anesthetized (1.5% isoflurane in O2)
and body temperature maintained at 37oC. LV internal diameter (LVID),
and LV posterior wall thicknesses (LVPW) at diastole (d) and systole (s)
were measured from short-axis M-mode images. LV ejection fraction (EF%)
was calculated as follows: LVEF% = [(LVIDd)3 – (LVIDs)3]/(LVIDd)3 × 100; LV
fractional shortening (FS%) was calculated as follows: LVFS% = (LVIDd –
LVIDs)/LVIDd × 100. Values were averaged from 3 beats.
Langendorff isolated heart preparations
Ex vivo cardiac function and the effects of acute PDE2 inhibition
were evaluated in murine hearts set-up in Langendorff mode, as we have
described previously(53). Acute changes in these parameters were recorded
in response to bolus injections of ANP (0.01-10 nmol), the NO-donor sodium
nitroprusside (SNP; 0.01-10 nmol), the endothelium-dependent vasodilator
acetylcholine (ACh; 0.1-1.0nmol), and the β-agonist isoproterenol (ISO; 1-100
pmol) in the absence and presence of BAY 60-7550 (100 nM).
Histology staining and imaging
The isolated left ventricles were cut transversely below the mitral valves,
fixed in 10% formalin for 24h, then stored in 70% alcohol before embedding
in paraffin wax and sectioning.
Wheat germ agglutinin fluorescence staining
Ventricular myocyte size was determined by staining heart sections with
a fluorescent cell membrane antibody, wheat germ agglutinin alexafluor
647(Molecular Probes, Invitrogen, UK) and mounted with Prolong gold DAPI
mountant as per standard immunohistochemistry protocols. Images were
taken on a Zeiss 710 confocal microscope and the cardiomyocyte size ana-
Fig. 8. PDE2 inhibition augments cardiac cGMP, but not cAMP, levels in vivo
and promotes the anti-hypertrophic effect of NO, but not ANP, in isolated
cardiomyocytes. (A) Cardiomyocyte area in cells isolated from neonatal WT
mice treated with AngII (100 nM) for 24 h in the absence and presence
of the NO donor DETA-NONOate (DETA; 10 μM), atrial natriuretic peptide
(ANP; 1 μM) or brain natriuretic peptide (BNP; 1 μM) under basal conditions
or following treatment with BAY 60-7550 (100 nM). (B) Cyclic nucleotide
levels in whole heart homogenates from sham mice or animals subjected to
abdominal aortic constriction (AAC) for 6 weeks in the absence and presence
of BAY 60-7550 (10 mg/kg/day; p.o.). (C) Immunoblot analysis of PDE2A
expression in whole heart homogenates from mice subjected to abdominal
aortic constriction (AAC) for 6 weeks in the absence and presence of BAY 60-
7550 (10 mg/kg/day; p.o.; initiated at 3w). Data are expressed as mean±sem
with analysis by one-way ANOVA with Bonferroni post hoc test. *p<0.05 v
AngII + DETA-NONOate (A), **p<0.01 v sham and #p<0.0 v AAC (B), *p<0.05
v sham (C). n=6.
lyzed with Image J (NIH). Cardiomyocyte size was estimated with investigator
blinded to treatment type and as an average of approximately 400 cells per
heart.
Picrosirius red staining
Tissue slides were dewaxed, rehydrated and stained using a Picrosirius
Red Stain kit following the manufacturer’s instructions (Polysciences, Inc.
Warrington, PA, USA. A Nikon Eclipse TS100 microscope (Nikon UK Limited,
Surrey, UK) was used to capture images of the stained slides. Images were
analysed by threshold analysis using Image J with investigator blinded to
treatment type.
Primary cardiomyocyte isolation and culturing
Primary cardiomyocytes were isolated using the Pierce primary car-
diomyocyte isolation kit (Thermofisher Scientific, Crawley, UK) with minor
modifications. Briefly, individual neonatal hearts from 1-3 day old mice
were minced, treated with Cardiomyocyte Isolation Enzyme 1 (with papain)
and Cardiomyocyte Isolation Enzyme 2 (with thermolysin) The resulting
isolated CMs were seeded into gelatin (0.1%) pre-coated 12-well plates, and
incubated in DMEM for three days till confluent. The cells were then serum
starved for 24 h before treatment with Angiotensin (Ang) II (1µM) for 24
hours in the absence and presence of the NO donor DETA-NONOate (DETA;
10 μM), atrial natriuretic peptide (ANP; 1 μM) or brain natriuretic peptide
(BNP; 1 μM) under basal conditions or following treatment with BAY 60-7550











































































































































0 h (baseline) and 24 h. Image J was used to analyze the cardiomyocyte size.
An average of 30 cells per heart, and 5-7 hearts per treatment were analyzed.
Quantitative RT-PCR, immunoblotting & immunohistochemistry
Whole hearts were homogenized using QIAshredder technology and
RNA was extracted using a standard extraction kit (Qiagen, UK). RNA was
quantified using a NanoDrop spectrophotometer (Thermofisher Scientific,
MA, USA) and 1 μg converted to cDNA by reverse transcription (High Capacity
RNA-to-cDNA Kit; Applied Biosystems, Life technologies Ltd, UK). Specific
primers for PDE2A(54), hypertrophic or fibrotic markers and housekeeping
genes RLP-19 and β-actin (300 nM; detailed in SI Appendix, Table S2) were
added to cDNA template and SyBr Green quantitative PCR mix (Quantitect
Sybr green kit, Qiagen, UK). 20 ng of cDNA from each sample was amplified
using quantitative real-time PCR over 40 cycles (initial denaturation: 10 min
at 95°C; cycling: 45 cycles, 10 s at 95°C, 15 s at 57°C, and 5 s at 72°C; melt:
68-90°C). mRNA expression was analyzed by expressing the cycle threshold
(Ct) value as 2-ΔΔCt and normalized to both housekeeping genes (RPL-19 and
β-actin).
PDE2A protein expression was determined by immunoblot using pri-
mary anti-PDE2A antibody (Santa Cruz Biotechnology, USA; 1:500) and
secondary horse-radish peroxidase conjugated anti-goat IgG antibody (Santa
Cruz Biotechnology; 1:10,000). Bands were quantitated by densitometry
using ImageJ and normalized to the loading control, anti-GAPDH (1:50,000,
Thermo Fisher Scientific, UK) and secondary antibody horse-radish peroxi-
dase conjugated anti-mouse IgG (1:5,000; Dako, Cambridge, UK).
PDE2A localisation was assessed in heart sections by employing con-
jugated wheat germ agglutinin (WGA, Alexafluor 647, Molecular Probes,
Invitrogen, UK) staining to outline cardiomyocyte boundaries. Slides were
then double-stained with anti-PDE2A antibody (Santa Cruz Biotechnology,
as above) and mounted with Prolong Gold DAPI mountant as per standard
immunohistochemistry protocols. All slides were imaged using a Hamamatsu
nanozoomer S60 (x40 magnification).
TUNEL (terminal deoxynucleotidyl transferase mediated dUTP Nick End
Labeling) staining was conducted to assess levels of apoptosis in heart
sections using a commercially-available kit (MK500; Takara Bio. Inc., Kusatsu,
Japan). All slides were imaged using a Hamamatsu nanozoomer S60 (x20
magnification). TUNEL-positive cells and DAPI-stained nuclei were manually
counted by quantitative image analysis using Image J. A positive control con-
sisting of paraffin embedded sections of rat mammary gland were supplied
as part of the kit.
PDE2 activity
PDE2 activity in whole heart homogenates was determined by assaying
the concentration of cGMP and cAMP in the absence and presence of BAY
60-7550 (10 mg/kg/day) in vivo using commercially available kits (Direct cGMP
and Direct cAMP; Enzo Life Sciences, Exeter, UK).
Data analysis
Results are expressed as mean±s.e.mean, and P<0.05 denotes signif-
icance. The n value denotes the number of animals used in each group
and data were analyzed (GraphPad Prism version 5; GraphPad, La Jolla, CA,
USA) using one-way or two-way ANOVA with a Bonferroni post hoc test as
appropriate.
RESULTS
PDE2 inhibition reverses experimental HF in response to
pressure-overload
Abdominal aortic constriction (AAC) brought about a sus-
tained increase in MABP (SI Appendix, Table S3) and an archety-
pal HF phenotype as expected, comprising reduced contractil-
ity, LVH and LV dilatation (Figure 1). Cardiomyocyte size and
Picrosirius red staining were also increased, indicative of a hy-
pertrophied and fibrotic LV (Figure 1 & SI Appendix, Figure S2).
Administration of BAY 60-7550 at week 3 resulted in a significant
reversal of each of these indices of disease severity (Figure 1 & SI
Appendix, Figure S1); indeed, in some cases the salutary effect of
PDE2 inhibition was so pronounced that structure (e.g. cardiomy-
ocyte size) and function (e.g. ejection fraction) were ostensibly
returned to normal levels (Figure 1). Importantly, administration
of BAY60-7550 did not cause a significant reduction inMABP (SI
Appendix, Table S3), excluding the possibility that PDE2 inhibition
may lead to peripheral dilatation and a reduction in the cardiac
overload, thereby indirectly dampening the HF phenotype; nor
did BAY 60-7550 overtly alter HR (Table 4). These findings verify
a substantial, multi-faceted protective effect of PDE2 inhibition
in HF.
The beneficial effects of PDE2 inhibition in pressure
overload-induced HF are not underpinned by acute changes in
cardiac function
One potential mechanism by which PDE2 inhibition might
bring about a beneficial effect in the setting of HF, in terms
of myocardial function, would be to exert an acute, positive
inotropic effect thereby augmenting contractility. To rule this
out, hearts from sham animals and mice undergoing AAC were
isolated and set up in Langendorff mode to assess the effects
of BAY 60-7550 per se, and on the actions of cGMP (i.e. NO
and natriuretic peptides) and cAMP (isoproterenol) –elevating
agents. Cardiac structure and function were recorded longitudi-
nally by ECHO to ensure a HF phenotype was established in
the mice undergoing AAC and this was corroborated by initial
data from the hearts ex vivo which exhibited reduced contractility
and impaired coronary function (SI Appendix, Figure S3). BAY
60-7550 caused a modest, yet significant fall in CPP in isolated
hearts indicative of a subtle vasodilator effect (Figure 2). This
vasorelaxant activity was present regardless of whether the hearts
were isolated from sham animals or mice with HF. Addition
of ANP caused a dose-dependent reduction in CPP but had
little or no effect on contractility (i.e. LVDP) or HR (Figure
2). These responses were neither affected by the presence of
BAY 60-7550 nor in failing hearts. Bolus delivery of SNP also
caused a dose-dependent fall in CPP, was devoid of activity
against LVDP, but tended to increase HR (Figure 2). Again,
this profile was maintained in sham and failing hearts, and in
the absence and presence of BAY 60-7550; the only exception
being a reduction in vasodilation in response to PDE2 inhibition
in hearts from AAC animals (Figure 2). Finally, isoproterenol
caused a dose-dependent drop in CPP with a concomitant, overt
increase in LVDP and HR, as anticipated of a cAMP-elevating
agent. This coronary vasodilator activity and positive inotropic
and chronotropic action were equivalent in sham and failing
hearts and in the presence of BAY 60-7550 (apart from a slight
reduction in coronary vasodilator activity with PDE2 inhibition
in failing hearts; Figure 2). BAY 60-7550 was unable to augment
the positive inotropic and chronotropic actions of isoproterenol
in this setting, establishing that metabolism of the pool of cAMP
that regulates contractility and rate in sham or failing hearts is
not a key role for PDE2; this dovetails well with a lack of effect of
BAY 60-7550 on HR in vivo (SI Appendix, Table S4). These data
clearly demonstrate that the favorable effects of BAY 60-7550 are
not underpinned by an acute action on cardiac contractility but
rather exerted via a more extensive, chronic influence on heart
morphology (and potentially additional mechanisms including
autonomic regulation(55, 56)).
PDE2 inhibition reverses pressure overload-induced HF in
GC-A-/- mice
We next sought to determine which arm of the guanylyl
cyclase enzyme family was responsible for generating the pool of
cGMP regulated by PDE2. Since our previous work in PH had
highlighted a link between PDE2 and natriuretic peptide/GC-A-
dependent cGMP synthesis, and the fact that genetic deletion of
ANP, BNP or GC-A results in cardiac structural and functional
deficits at baseline (12-14), we investigated the efficacy of BAY
60-7550 in pressure overload-induced HF in GC-A-/- mice. Un-
expectedly, the beneficial effects of PDE2 inhibition on cardiac
structure and function in AAC-drivenHF inWTmice were main-
tained in GC-A-/- animals (Figure 3). As published previously,
the GC-A-/- animals had marked intrinsic cardiac hypertrophy
and dilatation (albeit with preserved ejection fraction; (Figure 3).
Nonetheless, the reduction in contractility, increase in ventricular
wall thickness & mass, and fibrotic burden were all significantly
reversed in the presence of BAY 60-7550 (Figure 3); PDE2i also
caused a reduction in cardiomyocyte size. Indeed, the positive
pharmacodynamic profile of BAY 60-7550 was of a magnitude
similar to that observed in WT mice (Figure 1). Such findings
argue against a significant contribution of ANP/BNP signaling to











































































































































Obligatory role of NO/GC-1α signaling in the beneficial ef-
fects of PDE2 inhibition
As a result of the preserved pharmacology of BAY 60-7550
in GC-A-/- mice, we turned to exploration of a potential role
for the NO/GC-1/cGMP. We took two approaches; first, using a
transgenic strain with global deletion ofGC-1α subunit (GC-1α-/-)
and second, treatingWT animals with the NO synthase (NOS) in-
hibitor NG-nitro-L-arginine methylester (L-NAME). The cardio-
vascular phenotype of the new GC-1α-/- strain generated herein
mirrored that reported previously(57, 58) with loss of GC-1α
protein, reduced vasorelaxant and cGMP-generating capacity of
NO donors, and sex-dependent hypertension (SI Appendix, Figure
S1).
GC-1α-/- mice exhibited a subtle cardiac phenotype at base-
line, with a modest rise in LVID and increased cardiomyocyte
size (albeit without a significant increase in (LV:BW ratio) in
comparison to WT (Figure 4). In response to AAC, GC-1α-/-
animals exhibited an almost identical phenotype toWTmice with
reduced cardiac contractility, enlarged and dilated LV, and in-
crease in fibrosis. Of note, the baseline cardiomyocyte size in GC-
1α-/- animals was increased compared to WT and consequently
AAC only marginally increased this index of hypertrophy (Figure
4). The mechanism underpinning the innate cardiomyocyte en-
largement, but normal LV mass, in GC-1α-/- animals is not a
result of cardiomyocyte loss since levels of apoptosis were not
different to WT (SI Appendix, Figure S4); the reason for this
intrinsic difference remains to be explained. Regardless, in sharp
contrast to WT and GC-A-/- mice, PDE2i did little or nothing to
improve the cardiac function in GC-1α-/- animals (Figure 4). To
substantiate this critical involvement of NO/GC-1/cGMP signal-
ing in the salutary effects of PDE2i, essentially identical studies
were conducted in WT mice receiving L-NAME (SI Appendix,
Figure S5). First, the consequences of pan-NOS inhibition per se
on cardiac function following AAC were minimal, reflecting the
phenotype ofGC-1α-/- animals. Second, mirroring observations in
GC-1α-/- mice, the pharmacodynamic benefit of BAY 60-7550 was
completely absent, including effects to reverse the fibrotic burden
that had beenmaintained inGC-1α-/- animals (SI Appendix, Figure
S5). Notably, GC-1α expression tended to be up-regulated in
response to pressure overload (SI Appendix, Figure S2). These
data provide genetic and pharmacological verification that it is
the NO-driven arm of cGMP signaling that is responsible for the
positive effects of PDE2i in HF.
PDE2 inhibition reverses experimental HF in response to
sympathetic hyperactivation in a NO/GC-1α-dependent, but GC-
A-independent, manner
In order to demonstrate that PDE2 inhibition has a generic
salutary effect in experimental models of HF the efficacy of BAY
60-7550 was also explored in isoproterenol-driven (i.e. sympa-
thetic hyperactivation) cardiac dysfunction. Akin to pressure-
overload, PDE2i brought about a multi-modal protection to re-
verse the cardiac contractile changes (in this instance more anal-
ogous toHFwith preserved EF;HFpEF), LV hypertrophy and di-
latation, and cardiac fibrosis (Figure 5). Furthermore, substantiat-
ing the concept that PDE2i augments NO/GC-1α signaling in HF,
the positive outcome realized by BAY 60-7550 was maintained in
GC-A-/- mice (Figure 6) but diminished or lost in GC-1α-/- animals
(Figure 7). Interestingly, genetic deletion of GC-A transformed
the predominantly HFpEF phenotype produced by isoproterenol
to HF with severely impaired EF resulting in death in many
animals (Figure 6), confirming the critical role(s) of endogenous
natriuretic peptide signaling in preserving cardiac function in
HF(14). Yet, BAY 60-7550 was still able to reverse this pathology
and significantly improve mortality (Figure 6), proffering further
evidence that targeting NO/GC-1 signaling is pharmacologically
beneficial in HF; a thesis strengthened by the lack of efficacy of
BAY 60-7550 in GC-1α-/- mice exposed to isoproterenol (Figure
7). A global comparison of the cardiac structural and functional
indices in pressure overload-induced HF inWT, GC-A-/- and GC-
1α-/- mice is depicted in SI Appendix, Figure S6.
This model, characterized by excessive β-
adrenoceptor/cAMP signaling also served as a means to
tease out any cAMP-driven effects of PDE2 inhibition. In
this regard, however, BAY 60-7550 did not exert any positive
chronotropic effects (SI Appendix, Table S4).
PDE2 inhibition boosts the anti-hypertrophic effect of NO,
but not natriuretic peptides, in isolated cardiomyocytes
To corroborate the importance of NO/GC-1/cGMP signaling
to the HF phenotype, we followed up in vivo investigations with
in vitro studies in isolated cardiomyocytes. Here, addition of NO,
ANP and BNP reduced the hypertrophic response (i.e. cardiomy-
ocyte area) to Angiotensin (Ang) II (Figure 8). Notably, however,
the reduced hypertrophic response to NO, but not ANP nor BNP,
significantly increased in the presence of BAY 60-7550 (Figure 8).
This in vitromodel of cardiomyocyte hypertrophy presents further
evidence of the compartmentalization of NO/GC-1/cGMP signal-
ing with PDE2 in murine hearts.
PDE2 inhibition augments cardiac cGMP, but not cAMP,
levels
To explore the cGMP- and cAMP hydrolyzing activity of
PDE2 in healthy and failing hearts, cardiac cyclic nucleotide
concentrations were determined in the in vivo models. AAC
increased cGMP levels modestly (∼50%) in WT animals but
these values were markedly enhanced (∼300%) following ACC
in the presence of BAY 60-7550 (Figure 8), indicating that PDE2
activity is markedly upregulated in HF and plays a central role
in curbing cGMP signaling. This pattern of activity was entirely
absent inGC-1α-/- hearts butmaintained inGC-A-/- hearts (Figure
8), paralleling the in vivo functional pharmacology. In contrast,
BAY 60-7550 was unable to influence global cAMP levels in WT
animals with AAC (Figure 8), which fits with previous reports of
compartmentalized effects of PDE2 inhibition on local pools of
cAMP(40) (which would entail a lack of effect on overall cardiac
cAMP concentrations); alternatively, PDE2 may not play a key
role in cAMP metabolism in this setting.
Finally, the expression of PDE2A was upregulated in hearts
from mice undergoing AAC (Figure 8), consistent with published
data in animal models and patients with HF(39); however, this
recognized increase in PDE2A was not as pronounced in the
sympathetic hyper-activation model (SI Appendix, Figure S2), de-
spite the clear pharmacological benefit of PDE2i; this suggests the
trigger(s) for promoting PDE2A expression is specific to pressure
overload rather than enhanced sympathetic drive. In addition,
PDE2A appeared to exhibit somewhat of a sarcomeric local-
ization (i.e. a striated staining pattern) but this did not change
patently in the face of pressure overload, implying that PDE2A
localization does not spatially adjust during HF to physically
associate with a different cGMP pool (SI Appendix, Figure S7).
PDE2 inhibition reduces the expression and/or activity or a
number of pro-hypertrophic and pro-fibrotic signaling pathways
To glean molecular insight into the downstream pathways
coupled to NO/GC-1α signaling in the context of PDE2i in HF
we employed quantitative PCR to interrogate a number of es-
tablished cardiac hypertrophic and fibrotic mediators(59). Here,
administration of BAY 60-7550 resulted in reduced expression
of a number of pro-fibrotic markers (e.g. Col1α1 and Col1α2)
and drivers (e.g. TGFβ, CTGF), albeit without affecting ColIVα1
or fibronectin (SI Appendix, Figure S8); this profile matched the
strong anti-fibrotic effect observed in vivo. The anti-hypertrophic
action of PDE2i documented in vivo was supported by a signif-
icant reduction in ANP and βMHC expression, but this did not











































































































































hypertrophic pathways such as NFAT or GSK3β (SI Appendix,
Figure S8).
DISCUSSION
The strategy of promoting cardiac cGMP signaling, by dual neu-
tral endopeptidase/angiotensin receptor blockers or sGC stimu-
lators, is clinically effective in HF(15, 23). Blockade of several
PDE isoforms, including PDE1(25), PDE5(27), or PDE9(28), has
shown promise in experimental models of HF suggesting target-
ing these cGMP-hydrolyzing enzymes may also offer therapeutic
gain, although a large-scale clinical evaluation of PDE5 inhibi-
tion in HFpEF patients did not meet its primary endpoint(37).
Previous work has demonstrated positive pharmacology through
inhibition of an additional PDE isozyme, PDE2, in restoring
pulmonary hemodynamics, vascular remodeling and RVH in pre-
clinical models of PH(46). Increased expression and activity of
PDE2 in experimental models(60, 61) and patients with HF(39)
provides support for also targeting this isozyme in HF; however,
previous studies have largely focused on the cAMP-hydrolyzing
capacity of the enzyme, with both positive(44) and negative(39)
outcomes. The present study took a functional approach to eval-
uate the capacity of PDE2 as a cGMP-hydrolyzing enzyme to
modulate the pathogenesis of experimental HF. Using both pres-
sure overload and isoproterenol -induced LVH and cardiac dys-
function, we describe that PDE2A expression and activity is up-
regulated as a consequence of disease, and that PDE2 inhibition
proffers a multi-pronged protective effect. In both models, the
decline in contractility, LVH, LV dilatation and fibrotic lesions
were halted, and often reversed, by administration of the selective
PDE2i BAY 60-7550. This was mirrored, at a more molecular
level, by increases in cardiac cGMP (but not cAMP) levels and
diminution of a range of hypertrophic and fibroticmarkers. These
observations suggest PDE2 plays a central role in the reduced
cGMP signaling that has been shown to characterize HF, at least
in experimental models, leading to misaligned myocardial ener-
getics, compromised cardiac performance, and coronary vascular
dysfunction(62). Moreover, that inhibition of this PDE isozyme
may represent a novel means with which to promote cardiac
cGMP signaling for therapeutic gain.
In order to determine if the beneficial effects of PDE2 inhibi-
tion in experimental HF were dependent on cGMP derived from
NO- or natriuretic peptide- sensitive GCs, we conducted parallel
studies in animals deficient in either cGMP-dependent signaling
system. In this setting, the positive effect of BAY 60-7550 on
cardiac dysfunction was maintained in GC-A-/- mice (the cognate
receptor for ANP and BNP(63)), but absent in animals harboring
a genetic deletion of GC-1α. In a logical extension to these
findings, studies were repeated in animals treated chronically with
the non-selective NOS inhibitor L-NAME; an identical response
profile was observed in that the efficacy of BAY 60-7550 apparent
inWTmice was completely abrogated. This finding indicates that
the up-regulation of PDE2 curtails, specifically, NO/GC-1/cGMP
signal transduction to exert a cardioprotective benefit in HF,
but does little or nothing to alter natriuretic peptide-triggered
pathways which are well-established to be anti-hypertrophic and
anti-fibrotic(13, 14, 63). Indeed, this differential mechanism of
action is illustrated perfectly in the sympathetic hyperactivation
model, where genetic deletion of GC-A-/- resulted in significant
mortality (i.e. inherent cardioprotective function of ANP/BNP)
but rescued by administration of BAY 60-7550 (i.e. augmenting
NO/GC-1 signaling). These data suggest that PDE2 inhibitors
may be an effective means by which to promote cardioprotective
NO/GC-1/cGMP signaling and offset the deterioration in LV
function typical of HF patients.
These data align well with the observation that PDE2 can
be allosterically-activated by NO/GC-1-derived cGMP to mod-
ulate cAMP bioactivity in cardiac myocytes(40). However, in
terms of functional cGMP effects, cell-based studies have inti-
mated that membrane-bound PDE2 is more efficient in hydrolyz-
ing particulate GC-generated cGMP as a result of intracellular
compartmentalization(26). Nevertheless, the co-localization of
GC-1with chaperones that promote associationwith the cytoplas-
mic membrane (e.g. Hsp70(64) and Hsp90(65)), does provide the
rationale for a local pool of GC-1-generated cGMP in close prox-
imity to PDE2. This concept is supported by nNOS translocation
to the plasma membrane in failing hearts(66), and that caveolin-
binding protects GC-1 from translocation, oxidation and loss of
NO-sensitivity in response to volume overload(67, 68). A similar
pattern of activity was observed in terms of changes in coronary
flow in isolated hearts. Here, BAY 60-7550 caused a modest
vasodilatation in hearts fromWTandGC-A-/- mice, but this effect
was absent in hearts lacking GC-1α; again, this suggests PDE2
blockade enhances signaling by (endothelium-derived) NO/GC-
1 in the coronary vasculature. This dilator effect on coronary
function, albeit modest, would be a welcome additional action
of PDE2 inhibitors in the context of HF since it would promote
increased blood flow to the myocardium. Interestingly however,
PDE2 inhibition did not augment SNP-induced vasodilatation in
the coronary circulation, suggesting it might exert a subtle effect
on endothelium-derived NO bioactivity rather than on agonist-
stimulated dilatation. Despite the pharmacological benefit of
PDE2 inhibition and augmentation of NO/GC-1/cGMP signaling
in HF models in WT mice, we noted that genetic deletion of GC-
1α did not cause a significant intrinsic deterioration in the cardiac
dysfunction associated with AAC. This fits with previous work
reporting that eNOS-/-, GC-1α-/- and cardiomyocyte-specific G-
kinase (cGK)I-/- mice do not exhibit exacerbated LVH in response
to pressure overload in the context of hypertension(58, 69) and/or
AAC(50, 70) (although more stringent thoracic aortic constric-
tion does tease out an aggravated phenotype(71, 72)). The reason
for this apparent disconnect is almost certainly the release of
natriuretic peptides upon cardiac stress, which is sufficient to
maintain relatively intact cardiac structure and function(69). This
observation therefore suggests that NO/GC-1/cGMP signaling
does not innately impact the development of LVH and HF, but
can be harnessed pharmacologically to provide a therapeutic
benefit. This is despite the fact that GC-1α expression tends to
be up-regulated in response to pressure overload. The logical
explanation for this is that impairment of this signaling cascade,
for example through eNOS uncoupling(10), GC-1β heme oxida-
tion(8, 67), and/or up-regulation of PDEs(25, 27, 28), diminishes
its influence to such an extent that only under circumstances
of pharmacological augmentation can it meaningfully affect dis-
ease progression. The downstream signaling pathways driven by
PDE2-regulated cGMP pools to bring about this beneficial action
onNO/GC-1 signaling warrant further investigation. Involvement
of cGKI in the anti-hypertrophic and anti-fibrotic actions of
cGMP does not always appear to be a prerequisite (70, 73-75) but
the kinase is known to modify well-established targets including
Ca2+ channels and Ca2+ sequestration(17, 18), calcineurin/NFAT
signaling(19), RGS (20), transient receptor potential cation chan-
nel (TRPC) 6(21) and myosin binding protein (MBP)-C(22). Ac-
tivation of cGKII might represent an alternate pathway since this
cGK isoform in tandem with PDE2 is responsible for governing
aldosterone production in the adrenal cortex (76). Reports that
PDE2 regulates the cGMP-dependent sympatholytic effects of
NO and natriuretic peptides (55, 56) also proffers an intriguing
mechanism that might underlie the benefits of PDE2 inhibition
in HF.
One explanation for the beneficial effects of PDE2 inhibition
on the HF phenotype could be an acute positive inotropic effect
via augmentation of cAMP signaling (since this PDE isozyme
metabolizes both cGMP and cAMP), which would tend to func-











































































































































been reported previously in mice using BAY 60-7550 or animals
over-expressing a cardiac-specific PDE2(43). To test this possi-
bility, isolated hearts from WT, GC-1α-/- and GC-A-/- mice that
had undergone pressure-overload or sham surgery were set-up
in Langendorff mode. Whilst the lack of sympathetic innervation
represents a patent caveat in this setting, it enables examination
of more acute responses in the myocardium and coronary vascu-
lature, with sympathetic stimulation being mimicked by adminis-
tration of isoproterenol. In hearts removed from animals exposed
to AAC, myocardial contractility and coronary vascular function
were both impaired compared to hearts from sham-operated
animals, commensurate with aHF phenotype. Importantly, whilst
BAY 60-7550 had a small effect to increase coronary flow in both
normal and failing hearts, it was unable to alter any inotropic
or chronotropic effects of NO-donors, ANP or isoproterenol.
Also, there was no observable change in HR in the presence
of BAY 60-7550 (as an index of cardiac cAMP functionality)
in either pressure overload or isoproterenol –induced HF. In
concert, these observations suggest that PDE2 inhibition has little
or no acute effect on cardiac function, even in the face of β-
receptor stimulation, and therefore that the beneficial effects we
report in experimental HF in vivo are longer-term actions on
heart structure and the hypertrophic/fibrotic response. Curiously,
these observations seem at odds with recent data describing
positive chronotropic effects of BAY 60-7550 in mice with acute
or chronic β-adrenoceptor activation(43); whether the lower in
vivo dose in the present study (10 mg/kg/day s.c. v 3 mg/kg bolus
i.p.) explains the lack of effect on cAMP signaling remains to be
established (even if that is the case it means a tenable window of
opportunity exists permitting differentiation between cGMP and
cAMP, if required). Conversely, a parallel approach employing
transgenicmice over-expressing cardiac-specific PDE2 revealed a
significant increase in LV mass at baseline and following MI(43),
which would dovetail well with a cardioprotective role for PDE2
underpinned by cGMP.
Recent work has revealed PDE2 to change its substrate pro-
file in the LV based on the dynamic levels of cGMP and cAMP.
Thus, under physiological circumstances PDE2 hydrolyses cGMP
almost exclusively, whereas in the presence of β-adrenergic acti-
vation PDE2 predominantly metabolizes cAMP, thereby restrict-
ing adrenergic signaling(26, 40, 61). Our data suggest that PDE2,
in experimentalmodels ofHF in vivo and in isolated hearts ex vivo,
acts primarily as a ‘cGMP-hydrolase’; however, although herein
we only provide a cursory inspection, PDE2A localization does
not appear to change overtly in response to pressure overload.
Yet, this does not rule out an effect of PDE2i on a local pool of
cAMP that promotes an anti-hypertrophic activity, as has been
recently reported(44); one shortcoming of the present study is
that such a confined change would not have been detectable in
the whole heart cyclic nucleotide analysis. Indeed, it would be ad-
vantageous to target PDE2 in HF if the enzyme regulated generic
anti-hypertrophic mechanisms involving both cyclic nucleotides
(without an overt effect on contraction/metabolic demand). In-
terestingly however, these observations are in contrast to con-
temporary reports describing crosstalk between CNP-triggered
cGMP accumulation and cAMP-driven increases in contractility
at the level of PDE3 in HF(77). Further investigation is required
to determine if the cGMP-elevating activity of PDE2i might
indirectly inhibit PDE3 in a similar fashion; again, our assessment
of global cyclic nucleotide levels would likely have missed such a
compartmentalized effect, but from a functional perspective (i.e.
inotropy) this did not seem to be an issue. Additionally, utilization
of GC-A-/- mice would not have brought to light an effect on CNP
signalling in this context since this natriuretic peptide triggers
cGMP generation via GC-B.
The differential activity of NO/GC-1 and natriuretic
peptide/GC-A signaling has important implications for the
pharmacological manipulation of cGMP for cardioprotective
purposes in HF. Ultimately, it seems likely that multiple
interventions, targeted at both the NO- and natriuretic
peptide–dependent GC/cGMP systems, will provide the optimal
pharmacological boost, since whilst there is overlap in the
two pathways (e.g. anti-hypertrophic and vasodilator) there
are clearly distinct consequences (e.g. anti-platelet versus
natriuretic). Thus, it is important that the compartmentalized
nature of cGMP (and cAMP) signaling is further delineated
with the aim of identifying the most efficient interventions
that can achieve this therapeutic goal. Whether this might be
inhibiting multiple PDEs, blocking breakdown with concomitant
cyclase activation, or most likely parallel activation of NO- and
natriuretic peptide– signaling pathways remains to be verified.
Herein, the efficacy of PDE2 inhibition is shown to be dependent
on intact NO/GC-1/cGMP signaling, as is the case for PDE5
inhibitors(78) (although this esterase may be re-targeted in
pathological circumstances(79)). As a consequence, increasing
cellular cGMP levels by pharmacological blockade of either
PDE2 or PDE5 would be predicted to activate the alternate
isozyme as a result of cGMP binding to N-terminal GAF
domains possessed by both enzymes(24). This may well explain,
at least in part, the lack of efficacy of sildenafil in the RELAX
trial, and more positive data in patients would be achieved by
dual inhibition of PDE2 and PDE5. However, if both these
PDEs are largely constrained to metabolizing NO/GC-1-derived
cGMP, then combined blockade of PDE2 and PDE9 (which
regulates natriuretic peptide-driven increase in myocardial
cGMP(28)) might be superior by promoting NO and natriuretic
peptide signaling concomitantly? The caveat here is systemic
hypotension as a potentially dose-limiting effect when combining
cGMP-elevating agents (and other emerging consequences such
as melanoma(80)), so titrating interventions to avoid these
concerns would be necessary.
In sum, this study provides convincing evidence in vitro and in
vivo of the therapeutic potential of PDE2 inhibition in LVH and
HF in promoting cardioprotective cGMP-signaling. The benefi-
cial effect of PDE2i is dependent on endogenous NO bioactivity
and stimulation of GC-1. Thus, PDE2 inhibition, possibly in com-
bination with other cGMP-elevating agents (e.g. PDE5 and/or
PDE9 inhibitors) offers a new approach for the treatment of LVH
and HF.
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